Sentences with phrase «stage cancer therapies»

Not exact matches

Revenue from selling Celgene's therapies will fund the company's late - stage pipeline, which boasts three new cancer therapy candidates in pivotal trials.

Higgins, S., Haffty, B. Pregnancy and lactation after breast - conserving therapy for early stage breast cancer.

Trinity is suffering from stage 4 cancer, and the medical bills & chemo therapy expenses are difficult for the family to cover.

«Depressed men with prostate cancer are diagnosed with later stage disease, and get less effective therapies.»

«Such advances in sequencing technology facilitate rational precision therapies for individuals with late - stage cancer.»

In addition, the study showed that the 5 - year survival rate for selected older patients with advanced lung cancer who were treated with surgical therapy was 29.9 % for Stage III and 26.7 % for Stage IV.

The test can help patients and their doctors to be more vigilant about screenings, potentially catching cancers at their earliest and more treatable stages, and to make more informed decisions about therapies that may improve survival and quality of life.

Now a team of researchers from Central South University in China have demonstrated that a technique known as photoacoustic imaging, which is already under investigation for detecting skin or breast cancers and for monitoring therapy, also has the potential to be a new, faster, cheaper and non-invasive method to detect, diagnose and stage cervical cancer with high accuracy.

«These findings will give women with early stage breast cancer greater certainty that anti-estrogen therapy will decrease their risk of recurrence and increase their chance for survival whereas chemotherapy will not,» said breast cancer survivor Mary Lou Smith, JD, MBA, who helped design the study as a leader in the ECOG - ACRIN Cancer Research Advocates Commcancer greater certainty that anti-estrogen therapy will decrease their risk of recurrence and increase their chance for survival whereas chemotherapy will not,» said breast cancer survivor Mary Lou Smith, JD, MBA, who helped design the study as a leader in the ECOG - ACRIN Cancer Research Advocates Commcancer survivor Mary Lou Smith, JD, MBA, who helped design the study as a leader in the ECOG - ACRIN Cancer Research Advocates CommCancer Research Advocates Committee.

«The good news is that this finding predicts that patients missing either gene should be sensitive to new therapies targeting focal adhesion enzymes, which are currently being tested in early - stage clinical trials,» says Shaw, who is also a member of the Moores Cancer Center and an adjunct professor at the University of California, San Diego.

«We found that CSM is statistically significantly lower for Asian Americans than for non-Hispanic whites overall, despite similarities in odds of receiving definitive therapy, and even after adjusting for socio - demographic factors, cancer stage and treatment,» said Trinh.

When factoring in what is now known about breast cancer biology and heterogeneity, breast conserving therapy (BCT) may offer a greater survival benefit over mastectomy to women with early stage, hormone - receptor positive disease, according to research from The University of Texas MD Anderson Cancer Ccancer biology and heterogeneity, breast conserving therapy (BCT) may offer a greater survival benefit over mastectomy to women with early stage, hormone - receptor positive disease, according to research from The University of Texas MD Anderson Cancer CCancer Center.

As targeted therapies take center stage in cancer treatment, they are profoundly changing the way research is done.

Advances in medical imaging technology which could make proton beam therapy a viable treatment for many more cancer sufferers will be described on an international stage.

«This groundbreaking study sets the stage for more exacting research, using the latest genomic technologies and aimed at developing new therapies that could help the tens of thousand of patients who urgently need our help,» said Dr. Nhan Tran, an Associate Professor of TGen's Cancer and Cell Biology Division and the study's other co-senior author.

Looking ahead, Chen says, «Ga -68-BBN-RGD could play an additive role in staging and detecting prostate cancer and provide guidance for internal radiation therapy using the same peptide labeled with therapeutic radionuclides.»

It is commonly thought that bladder cancers that develop after pelvic radiation tend to be aggressive, with high grades and stages, but this study found that the types, grades, and stages of bladder cancer that developed were similar in patients treated with and without radiation therapy.

«Unfortunately, due to the lack of screening mechanisms for many gynecologic cancers, they are often diagnosed in an advanced stage, thus leading to poor treatment response with standard therapies in many cases.

The researchers used the Surveillance, Epidemiology, and End Results (SEER) Database to identify 7,359 patients with advanced stage cervical cancer treated with external beam radiation therapy (EBRT) between 1988 and 2009.

Androgen deprivation therapy (ADT) is a common treatment option for patients with advanced stage prostate cancer.

«Patients with inoperable, early - stage lung cancer who receive stereotactic body radiation therapy have 40 % five - year survival rate.»

«Pancreatic cancer is a disease with a poor prognosis, mainly because of the inability to detect the tumor at an early stage, its high potential for early dissemination, and its relatively poor sensitivity to chemotherapy or radiation therapy,» according to background information in the article.

Notably, multiple Notch inhibitors are in various stages of clinical development as potential cancer therapies.

With the advancement of surgical and radiation therapy strategies for stage 1 non-small-cell lung cancer (NSCLC), more patients are being treated, resulting in higher survival rates, according to a study published online today in The Annals of Thoracic Surgery.

ura Oncology Inc., a clinical stage biopharmaceutical company that develops therapies for cancer patients, is now trading on the NASDAQ after an initial public offering.

Letrozole is approved by the FDA for the adjuvant treatment of early - stage breast cancer in postmenopausal women who have already been treated with 5 years of tamoxifen therapy.

ARandomized, Phase III, Double - Blind Placebo - Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum - Based Combination Chemotherapy in Advanced, Stage IIIB / IV Non-Small Cell Lung Cancer

Choy, H, Chakravarthy, A. Phase I trial of Irinotecan and concurrent radiation therapy for stage III non-small cell lung cancer.

A Phase II Single - Arm Trial to Investigate Tepotinib in advanced (Stage IIIB / IV) Non-Small Cell Lung Cancer with MET Exon 14 (METex14) Skipping Alterations After Failure of at Least One Prior Active Therapy, Including a Platinum - Doublet - Containing Regimen

SEATTLE, Feb. 05, 2018 (GLOBE NEWSWIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a landmark study in which Danish researchers used the Prosigna ® Breast Cancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andCancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andcancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andcancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 and 2003.

Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review.

Researchers found that shorter course of radiation therapy may provide lesser side effects for early stage breast cancer patients compared to the long - term treatments.

There are now multiple immunotherapies targeting clearance of alpha - synuclein from the brain in early - stage clinical trials, and multiple trials underway or in the works on the next generation of cell replacement therapies for dopaminergic neurons, including the TRANSEURO trial; the Summit4StemCell initiative, put together by Jeanne Loring — a researcher at The Scripps Research Institute who is exceptionally engaged with turning her research into therapies; a Japanese trial to be run by Jun Takahashi of Kyoto University in Japan (cf. here and here); and a trial centered at Memorial Sloan Kettering Cancer Center headed by cell biologist Lorenz Studer.

Join the Sibley breast cancer team to learn the latest on breast imaging, chemotherapy and hormonal therapy, Her2 targeted therapy with early stage breast cancer, making sense of breast cancer genetics, demystifying radiation treatment and fertility preservation.

Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.

The morphological assessment of the differentiation degree in breast cancer has been provided useful prognostic information and the histological grade forms part of the multifactor Nottingham prognostic index together with tumor size and lymph node stage, which is used to assure individual patient for proper therapy [17].

Oncologists commonly use this imaging technique to help locate tumors, establish the stage of those cancers» progression, and determine whether they have stopped growing in response to therapy or are relapsing or metastasizing.

Treatment of early stage breast cancer with lumpectomy, axillary dissection, and radiation therapy is considered by many to be relatively contraindicated in heavy women or women with large or

Research fields include translational research, invasion, metastasis, disseminated tumor cells, transcription, tumor - associated proteolysis, targeted therapy, micro-RNA, molecular staging of cancer.

One treatment for patients with early stage non-small cell lung cancer is a form of radiation called stereotactic body radiation therapy (SBRT).

12 Scientific Sessions Radiochemistry: Imaging of Cancer Other Tumors Basic Science Summary Session One Myeloma and Other Marrow Disorders Radiopharmacy: Quality Control and Validation Radiotherapy and Monitoring Therapy Basic Science Summary Session Two Pre-Clinical Systems Breast Cancer Prostate I: Initial Staging Quantification and Methodology of Oncology Studies Novel Radiochemistry: Radiometals

Such integrated approaches are used to investigate whether different subtypes or stages of a cancer can be distinguished, whether a cancer has the potential to spread, and whether a given therapy will be successful.

Ecker BL, Paulson EC, Datta J, Jeganathan AN, Aarons C, Kelz RR, Mahmoud NN: Lymph node identification following neoadjuvant therapy in rectal cancer: A stage - stratified analysis using the surveillance, epidemiology, and end results (SEER)- Medicare database Journal of Surgical Oncology 112 (4): 415 - 420,2015.

Mature results of a phase III randomized trial of bacillus Calmette - Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer stage I - III melanoma (E1673).

Weekly irinotecan and concurrent radiation therapy for stage III unresectable non-small cell lung cancer.

Vyriad's product pipeline encompasses multiple clinical - and preclinical - stage programs that target a broad range of cancer indications as well as programs that pair the company's oncolytic viruses with other cancer immunotherapy modalities, traditional cancer therapy, and newer targeted therapies.

The way the radiation therapy is given depends on the type and stage of the cancer being treated.

Chaired by Prof. Dirk Schadendorf, talks covered topics which included: melanoma epidemiology in the in period since the start of the German National Skin Cancer screening programme (Dr Andreas Strang); an overview of melanoma therapies used in stage IV melanoma; adjuvant therapies and prognosis in stage III melanoma (Dr Lisa Zimmer); tumour heterogeneity, plasticity and resistance in melanoma (Alexander Roesch); epigenomics of normal and abnormal cell differentiation (Bernard Horsthermeke); and, genetics and epigenetics of uveal melanoma (Michael Zeschnigk).

Vyriad is a clinical stage, biopharmaceutical company based in Rochester, Minn., that specializes in the development of powerful oncolytic virus therapies, using engineered viruses designed to selectively and rapidly destroy cancer.

Both the ovarian and prostate cancer trials could change clinical practice, with more women taking the drug bevacizumab (Avastin) to combat the disease in its advanced stages and more men getting radiation therapy for locally advanced prostate cancer, according to researchers who presented the findings Sunday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.